InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

InterCure Ltd.NASDAQ: INCR

Gross Profit · Q2 FY2025 · quarter ended Jun 2025

Gross profit declines year over year

Q2 FY2025 gross profit of ₪20.11M fell 3.4% year over year, ahead of the -47.9% change in trailing-twelve-month gross profit. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -40.2% a year.

Context

  • Gross profit amounted to 12.3% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -3.4% holds above the trailing-twelve-month pace of -47.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
₪20.11M+0.0% QoQ
Last fiscal yearDec 2025
₪33.18M+9.8% YoY
LTMJun 2025
₪40.61M-47.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.4%——
1 year+9.8%——
3-year CAGR-40.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

ILS · from the income statement

Latest · FY2025
33.18M ILS
Year-over-year change
+9.8%
4-year CAGR
-22.3%

Gross Profit vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.9% is the lowest of 7, against a peer median of +23.4%.
  • Gross profit amounts to 16.7% of revenue for INCR, versus a peer median of 60.3%.
INCR Competitors
Gross Profit for INCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMWLAmerican Well CorporationLTM Mar 2026$118M USD+1.9%+4.4%49.7%
ASRTAssertio Holdings, Inc.LTM Mar 2026$45.27M USD-38.7%-27.1%44.3%
FBIOFortress Biotech, Inc.LTM Mar 2026$42.68M USD+20.7%-2.0%64.5%
INCRInterCure Ltd.LTM Jun 2025₪40.61M ILS-47.9%-40.2%16.7%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$11.07M CAD+26.1%+7.2%60.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3M USD+337.0%—76.2%
CRDLCardiol Therapeutics Inc.LTM Mar 2026-CA$52.73K CAD+33.2%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$211K USD———
BMEABiomea Fusion, Inc.LTM Mar 2026-$593K USD———
Peer median (excluding INCR) —+23.4%+1.2%60.3%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.68M388.68M355.55M238.85M270.2M
Cost of Revenue128.55M233.6M250.46M208.61M237.02M
Gross Profit91.13M155.08M105.1M30.23M33.18M
Gross Margin41.5%39.9%29.6%12.7%12.3%
Research & Development1.24M632K388K414K390K
Selling, General & Admin53.46M97.32M86.24M84.63M80.41M
Operating Expenses62.95M104.46M146.66M97.44M26.45M
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
EBITDA31.17M70.23M(23.9M)(51.31M)(7.29M)
EBITDA Margin14.2%18.1%-6.7%-21.5%-2.7%
Operating Income28.19M50.63M(41.57M)(67.21M)6.73M
Operating Margin12.8%13.0%-11.7%-28.1%2.5%
Interest Income130K844K4.55M2.7M1.56M
Interest Expense5.05M14.69M24.22M20.65M19.66M
Other Income / Expenses(9.45M)(6.79M)(19.72M)(20.12M)(50.84M)
Income Before Tax18.74M43.84M(61.29M)(87.32M)(44.1M)
Pre-Tax Margin8.5%11.3%-17.2%-36.6%-16.3%
Income Tax Expense11.44M93K2.25M(14.53M)(7.32M)
Net Income4.69M44.82M(61.96M)(67.8M)(35.71M)
Net Margin2.1%11.5%-17.4%-28.4%-13.2%
EPS (Basic)0.120.99(1.36)(1.42)(0.63)
EPS (Diluted)0.110.99(1.36)(1.42)(0.63)
Weighted Avg Shares38.49M45.35M45.56M47.77M56.8M
Weighted Avg Shares (Diluted)40.84M45.35M45.57M47.77M56.8M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.